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Abstract
Background:  The promoter of the keratin 18 (K18) gen e  i s  5 -  t o  1 0 - f o l d  m o r e  a c t i v e  i n
tumorigenic (T-type) cell clones derived from the SW613-S human colon carcinoma cell line than
in non-tumorigenic (NT-type) clones. We have reported previously that the mechanism
responsible for this differential activity is acting on the minimal K18 promoter (TATA box and
initiation site). This mechanism does not require the binding of a factor to a specific site on the
DNA but involves the acetylation of a non-histone substrate. To get further insight into this
mechanism, we investigated the effect of the adenovirus E1A protein on the activity of the K18
promoter, both in T and NT cells.
Results: Wild type adenovirus E1A protein and C-terminal deletion mutants inhibit the K18
promoter, specifically in T-type cells. The domain responsible for this inhibitory effect is located in
the 12–25 region of the viral protein. E1A mutants that have lost this region but retain the PLDLS
motif (the C-terminal binding site for CtBP1) stimulate the K18 promoter, specifically in NT cells.
The inhibitory or stimulatory effects of the different E1A mutants are not dependent on a particular
sequence of the promoter. An E1A N-terminal deletion mutant carrying point mutations in the
PLDLS motif cannot stimulate the K18 promoter. CtBP1 interacts with CtIP, which is a known
partner of BRCA1, itself a component of the RNA polymerase II holoenzyme. The stimulatory
effect of two BRCA1 mutants, specifically in NT cells, implicates a tripartite BRCA1-CtIP-CtBP1
complex in the regulation of the K18 promoter.
Conclusion: Since we have shown previously that the K18 promoter is stimulated by deacetylase
inhibitors, specifically in NT cells, we conclude that the activity of the promoter is repressed in NT
cells by a mechanism involving the recruitment, by a BRCA1/CtIP complex, of CtBP1 and associated
deacetylases to the preinitiation complex. We propose a model depicting the mechanism
responsible for the differential activity of the K18 promoter between T and NT cells of the SW613-
S cell line.
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Background
The early region 1A (E1A) of adenoviruses encodes two
main proteins (243 and 289 aa-long in human adenovi-
rus 2) which are translated from alternatively spliced
mRNAs (12S and 13S, respectively). The two proteins
have identical N- and C-terminal regions but the larger
one (E1A-13S) has an additional domain (46 aa-long in
adenovirus 2) located in the central part of the protein.
Four regions that are conserved between several human
adenoviruses were named CR1, CR2, CR3 and CR4. In
adenovirus 2, CR3 almost coincides with the 46 aa-long
additional domain present in the E1A-13S isoform. The
E1A-12S and E1A-13S proteins are required to activate the
transcription of other viral genes. In addition, these pro-
teins interact with multiple cellular proteins to reprogram
the expression of many cellular genes in infected cells
(reviewed in [1-3]). This is necessary for the virus to repli-
cate its DNA and complete a productive cycle. The E1A
proteins were also found to be oncogenic in primary
rodent cells. This is a consequence of their ability to inter-
act with key cellular factors, including regulators of the
cell cycle such as the pocket proteins (Rb, p107, p130),
the related p300 and CBP coactivators of transcription or
the cyclin-dependent kinase inhibitors p21Cip1/Waf1 and
p27Kip1. Among the other cellular factors known to inter-
act with E1A are the TRRAP, p400 and CtBP1 proteins.
CtBP1 is a transcriptional corepressor. Several transcrip-
tional repressors recruit CtBP1 to promoters through a
conserved PXDLS motif. CtBP1 represses transcription
either directly or by subsequent recruitment of histone
deacetylases (HDACs) [4]. E1A proteins interact with
CtBP1 by a PLDLS motif located at the C-terminus of the
viral proteins [5]. A PLDLS motif is also present in the
binding site of the cellular CtIP protein, another interact-
ing partner of CtBP1 [4,6]. The function of CtIP in the cell
is unknown but it was found to interact with the BRCT
repeats of the BRCA1 tumor suppressor protein [7,8]. CtIP
binds to BRCA1 through a site distinct from the PLDLS
motif [9]. Thus, CtIP can act as an adapter protein
between BRCA1 and CtBP1.
We are interested in the mechanisms involved in tran-
scriptional deregulation of gene expression in the cells of
the SW613-S cell line derived from a human colon carci-
noma [10]. Analysis of cellular clones isolated from this
cell line indicated that it is heterogeneous and composed
of a mixture of two main cell types (named here T and
NT). T-type cells have a high level of amplification and
expression of the c-MYC gene, whose additional copies
are located on extrachromosomal elements (double
minute chromosomes). NT-type cells present a low level
of amplification of the oncogene and the supernumerary
copies are integrated into chromosomal DNA [11-14]. T
and NT cells markedly differ by several phenotypic traits
such as their tumorigenic potential in nude mice, capabil-
ity to grow in serum-free medium, sensitivity to the induc-
tion of apoptosis and cellular morphology [12,15,16].
Genes overexpressed in T cells, as compared to NT cells,
have been identified [12,17-20]. Among them, we chose
the keratin 18 (K18) gene to investigate the mechanism
responsible for its overexpression in T-type cells. We pre-
viously reported that this high level of expression is
mainly due to an increase in transcriptional rate [17] and
that, in transient expression assays, the K18 promoter is
much more active in T cells than in NT cells [21]. The
mechanism responsible for this higher activity is acting on
the minimal K18 promoter (TATA box and initiation site)
and does not involve the binding of a factor to a specific
site on the DNA [22]. We also found that an acetylation
mechanism acting on a non-histone substrate is driving
the high activity of the promoter in T cells [23]. In order
to get further insight into this mechanism, we now inves-
tigated the effect of the adenovirus E1A protein on the
activity of the K18 promoter, both in T and NT cells. This
protein has been widely used as a powerful tool to identify
and/or study important cellular regulatory proteins, in
particular factors involved in acetylation mechanisms
(p300/CBP, PCAF, TRRAP) [24]. Using a series of E1A
mutant proteins, we uncovered a role for the CtBP1 and
BRCA1 proteins in the functioning of the K18 promoter in
SW613-S cells.
Results
Wild type E1A and E1A mutants differentially inhibit or 
stimulate the minimal K18 promoter
We previously found that the adenoviral E1A-12S protein
has an inhibitory effect on the K18 promoter, specifically
in T-type cells of the SW613-S cell line. In contrast, a
mutant form of the protein, lacking the CR1 domain
(E1A-12S-∆CR1), has lost this inhibitory effect but gained
a stimulatory activity on the K18 promoter, specifically in
NT cells [23]. All the E1A mutants that we planned to use
in this work were derived from the E1A-13S isoform.
Therefore, the effect of the E1A-13S protein and of the
E1A-d30-76 mutant protein (equivalent to E1A-12S-
∆CR1) on the activity of the K18(80) promoter (-80 to
+21) was assayed. As shown in figure 1A, the E1A-13S pro-
tein has also a strong inhibitory effect on the promoter
activity in T cells whereas it has no significant effect in NT
cells. In contrast, the E1A-d30-76 mutant behaves like the
E1A-12S-∆CR1 protein and stimulates the activity of the
promoter, specifically in NT cells.
The promoter of the K18 gene comprises a TATA box and
an initiation site (minimal promoter) flanked by an Sp1
binding site (Fig. 1C). The minimal K18(41) promoter (-
41 to +21) has a low but differential activity between T
and NT cells. The flanking Sp1 binding site is essential for
a high activity of the promoter but not for its differential
behavior [21]. The effect of the E1A-13S protein and of theBMC Molecular Biology 2005, 6:8 http://www.biomedcentral.com/1471-2199/6/8
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Effect of E1A-13S or E1A-d30-76 proteins on the activity of the K18 promoter Figure 1
Effect of E1A-13S or E1A-d30-76 proteins on the activity of the K18 promoter. SW613-3 (T) or SW613-B3 (NT) 
cells were transfected with plasmid pK18(80)luc (A) or plasmid pK18(41)luc (B) alone (none) or in the presence of plasmid 
pE1A-13S or pE1A-d30-76, as indicated. Luciferase activities are expressed relative to that obtained with the reporter plasmid 
alone for each cell clone. Error bars represent the standard deviation of the mean of two experiments. (C) Structure of the 
promoter of the human K18 gene. The binding site of the Sp1 transcription factor, the initiation site (arrow at position -11; we 
have shown that the initiation is located 11 bp upstream of previously published +1 position [22]) and the TATA box are indi-
cated. Numbers indicate positions in nucleotides. K18(80) and K18(41), the two forms of the promoter inserted into luciferase 
expression vectors are shown.BMC Molecular Biology 2005, 6:8 http://www.biomedcentral.com/1471-2199/6/8
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Effect of E1A-13S or E1A-d30-76 proteins on the activity of mutated versions of the K18 promoter Figure 2
Effect of E1A-13S or E1A-d30-76 proteins on the activity of mutated versions of the K18 promoter. SW613-3 (T) 
or SW613-B3 (NT) cells were transfected with each of the reporter plasmids carrying the indicated mutated form of the 
K18(80) promoter, alone or in the presence of plasmid pE1A-13S (A and C) or plasmid pE1A-d30-76 (B and D). Luciferase 
activities are expressed relative to that obtained with the promoter construct alone in each cell line. Since the activities of all 
promoter constructs alone were adjusted to 100, they are all represented by a single pair of columns in each panel. The activity 
of these constructs relative to that of the wild type K18(80) promoter has been reported previously [22]. The structure of the 
various mutant forms of the K18(80) promoter is schematized in E. Error bars represent the standard deviation of the mean of 
duplicate experimental points.BMC Molecular Biology 2005, 6:8 http://www.biomedcentral.com/1471-2199/6/8
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E1A-d30-76 mutant was also assayed on the minimal
K18(41) promoter (Fig. 1B). The former inhibits the activ-
ity of the minimal promoter, specifically in T cells, and the
latter stimulates it only in NT cells, indicating that the Sp1
binding site is not essential for these effects. By muta-
tional analysis of the K18 minimal promoter, we have pre-
viously shown that the factor(s) responsible for its
differential activity between T and NT cells does not bind
to a specific DNA sequence [22]. Using the same mutant
constructs of the K18 promoter (Fig. 2E), we investigated
whether the inhibitory or stimulatory effects of the E1A-
13S and E1A-d30-76 proteins were also sequence-inde-
pendent. As shown in figure 2A–D, all the promoter con-
structs are inhibited by E1A-13S, specifically in T cells, and
are stimulated by the E1A-d30-76 mutant, only in NT
cells. These results suggest that, as for the differential activ-
ity of the promoter, the effect of these viral proteins is not
mediated by a factor which binds to a specific site on the
promoter but rather through alterations of protein-pro-
tein interactions within the preinitiation complex.
An N-terminal domain of E1A is involved in the inhibitory 
effect on the K18 promoter
In order to identify the region(s) of the E1A protein
involved in the inhibition of the K18 promoter in T-type
cells, we first used a series of N- or C-terminal deletion
mutants (Fig. 3A). All the C-terminal deletion mutants
have a comparable inhibitory effect on the activity of the
K18 promoter in T-type cells (Fig. 3B). Mutant E1A-C29,
which comprises only the N-terminal 29 aa, seems less
efficient at inhibiting the promoter. Further careful com-
parative analysis indicated that the inhibitory potency of
this mutant is about 60% of that of the E1A-13S protein
(data not shown). Some of the mutants also acquired an
inhibitory potential in NT cells but this point was not
explored further. None of the C-terminal deletion
mutants display a stimulatory effect on the promoter in
NT cells. The localization of the inhibitory domain in the
first 29 aa of E1A was confirmed by the analysis of N-ter-
minal deletion mutants (Fig. 3C). Mutant E1A-N25,
deleted of the first 25 amino acids, has lost the inhibitory
potential in T cells but has acquired the ability to stimu-
late the promoter in NT cells. This was also the case for all
the other N-terminal deletion mutants. The expression
level of the constructs coding for the E1A deletion
mutants was checked by Western blotting (Fig. 4A).
The results obtained with the N- and C-terminal deletion
mutants, assigning a role to the first 25 aa in the inhibitory
effect of E1A on the K18 promoter, were apparently con-
tradictory to those obtained with deletion mutants E1A-
12S-∆CR1 and E1A-d30-76 (see above). To solve this
issue, a series of small deletion mutants was constructed,
spanning the region of aa 2 to 85 (Fig. 5A). With the
exception of mutant E1A-d12-25, which has lost the
inhibitory potential in T cells (and acquired a stimulatory
effect in NT cells), all the other deletions in this region of
the protein have no influence on the inhibitory effect of
E1A and are unable to confer a stimulatory potential (Fig.
5B). In particular, mutants E1A-d26-35, -d30-45, -d40-60
and -d60-85, whose deletions span the region deleted in
mutant E1A-12S-∆CR1 and E1A-d30-76, have the same
properties as wild type E1A with respect to the K18 pro-
moter. The expression level of the E1A constructs used in
the above-described experiments was checked by Western
blotting (Fig. 4B). From all these results, we concluded
that region 12–25 of E1A is involved in its inhibitory
effect on the K18 promoter in T-type cells. The large dele-
tion carried by mutants E1A-d30-76 and E1A-12S-∆CR1 is
adjacent to the 12–25 domain. A possible explanation for
the results obtained with these mutants is that such large
deletions may perturb the conformational structure of the
molecule and functionally inactivates the 12–25 domain.
It has been reported [25] that E1A mutants with deletions
between residues 30–85 may not enter the nucleus,
despite the presence of an unaltered nuclear localization
signal at their C-terminus.
A C-terminal domain of E1A is involved in the stimulatory 
effect on the K18 promoter
As mentioned above, all the N-terminal deletion mutants
tested possess an activator effect on the K18 promoter,
specifically in NT cells (Fig. 3C). Mutant E1A-N190 com-
prises only the last 99 aa of E1A-13S. On the other hand,
none of the C-terminal mutants tested has acquired a
stimulatory activity on the promoter in NT cells (Fig. 3B).
From these results, we concluded that the region of E1A
responsible for the stimulatory effect is located in the C-
terminal part of the protein. The CtBP1 protein is known
to interact with the PLDLS motif present in this C-termi-
nal region of E1A [5]. To investigate a role for CtBP1 in the
stimulatory effect of this region on the K18 promoter in
NT cells, we used a previously characterized mutant of the
PLDLS domain [6]. A two aa change (PLDLS→PLASS)
destroys the capacity of binding to CtBP1 but does not
affect the nuclear localization signal which is located
nearby. We constructed the E1A-N190-mut281-282
mutant which is mutated on aa 281 (D→sA) and 282
(L→S). The binding of CtBP1 to E1A-N190 and the loss of
interaction with E1A-N190-mut281-282 were confirmed
by GST pull down assays and Western blotting (Fig. 6A).
In transient expression assays (Fig. 6B), the E1A-N190-
mut281-282 mutant cannot stimulate the K18 promoter
in the NT cells. This result indicates that the binding to
CtBP1 plays a role in the stimulatory effect of the C-termi-
nal region of E1A on the activity of the K18 promoter in
NT cells. This was confirmed by the observation that an
excess of CtBP1 protein can abolish the stimulatory effect
of E1A-N190 on the K18 promoter in NT cells (Fig. 6C),
although CtBP1 by itself has no effect on the activity of theBMC Molecular Biology 2005, 6:8 http://www.biomedcentral.com/1471-2199/6/8
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Effect of C-terminal and N-terminal deletion mutants of the E1A protein on the activity of the K18 promoter Figure 3
Effect of C-terminal and N-terminal deletion mutants of the E1A protein on the activity of the K18 promoter. 
(A) Schematic representation of the structure of the E1A-13S protein and of the deletion mutants. Know domains of E1A-13S 
(CR1, CR2, CR3 and CR4 and the N-terminal region) are shown as boxes. Numbers indicate positions in aa. (B and C) 
SW613-3 (T) or SW613-B3 (NT) cells were transfected with plasmid pK18(80)luc alone (none) or in the presence of the indi-
cated E1A constructs. Luciferase activities are expressed relative to that obtained with the pK18(80)luc plasmid alone. Error 
bars represent the standard deviation of the mean of at least two experiments.BMC Molecular Biology 2005, 6:8 http://www.biomedcentral.com/1471-2199/6/8
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Expression level of the E1A constructs Figure 4
Expression level of the E1A constructs. SW613-3 cells were transfected with plasmid constructs coding for the indicated 
wild-type or mutant E1A proteins. Cellular extracts were analyzed by Western blotting with an anti-E1A antibody. (A) N- and 
C-terminal deletion mutants. The E1A-C29, -C79 and -C109 polypeptides cannot be detected with this antibody. (B) Internal 
deletion mutants. Note that E1A and some of its mutants are very sensitive to proteolysis (white asterisks) in spite of the pres-
ence of protease inhibitors. Similar results were obtained in SW613-B3 cells (not shown).BMC Molecular Biology 2005, 6:8 http://www.biomedcentral.com/1471-2199/6/8
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promoter (Fig. 6D). The expression level of the E1A-N190
and CtBP1 vectors was controlled by Western blot analysis
(Fig. 7). A likely explanation for these results is that, in NT
cells, the K18 promoter is repressed by a mechanism
involving the binding of CtBP1 to the PLDLS motif of a
partner protein. Stimulatory mutants such as E1A-N190
disrupt this interaction and relieve the repressed state of
the promoter.
The differential activity of the K18 promoter and the
inhibitory or stimulatory effect of various E1A mutant
proteins are mediated by the minimal promoter ([22];
this work). No specific sequence of the promoter seems
necessary for these effects (see above) which likely result
from alterations in protein interactions in the preinitia-
tion complex. It was reported that the CtBP1 protein is a
corepressor which is recruited to promoters by DNA-
bound transcription factors [4]. Therefore, our observa-
tions raise the question of how this protein is recruited to
the preinitiation complex on the minimal K18 promoter.
CtBP1 interacts with the carboxy-terminal interacting pro-
tein (CtIP) [6], which is a known partner of the Rb, LMO4
and BRCA1 proteins. A complex comprising LMO4,
BRCA1 and CtIP was demonstrated in vivo [26]. The
direct recruitment of the Rb protein to the transcription
machinery has not been described to date but the pres-
ence of the BRCA1 protein in the RNA polymerase II
holoenzyme has been reported [27,28]. This observation
raises the possibility of a direct association of the BRCA1
protein with the preinitiation complex. The C-terminal
BRCT repeats of BRCA1 are responsible for the interaction
of this protein with CtIP [7,8]. The nonsense
Y1853→STOP mutation identified in some familial breast
cancers results in a 10-aa truncation of the second BRCT
repeat and prevents the interaction of the mutant protein
with CtIP. The possible effect of the wild type BRCA1 pro-
tein, of the BRCA1(Y1853→STOP) mutant and of a C-ter-
minal fragment of the BRCA1 protein comprising only the
BRCT repeats (pcDNA3-BRCT construct) on the activity of
the K18 promoter was tested (Fig. 8A). If the
BRCA1(Y1853→STOP) mutant has retained the capacity
to be incorporated into the preinitiation complex, it
should behave as a dominant negative mutant and stimu-
late the activity of the promoter, specifically in NT cells,
since it is unable to recruit the CtIP-CtBP1 complex. If the
BRCT fragment has lost the capacity to be incorporated
into the preinitiation complex, it should also behave as a
dominant negative mutant and stimulate the activity of
the promoter, specifically in NT cells, since it should
sequester the CtIP-CtBP1 complex away from the preiniti-
ation complex. Wild type BRCA1 has no effect on the
activity of the promoter in transient expression assays. The
BRCA1(Y1853→STOP) mutant and the BRCT fragment
do have a stimulatory effect on the activity of the K18 pro-
moter, specifically in NT cells. The expression level of the
BRCA1 constructs used in these experiments was assessed
by Western blotting (Fig. 8B and 8C). The apparent dom-
inant negative effect of the two BRCA1 mutants indicates
that the interaction of BRCA1 with CtIP plays an impor-
tant role in maintaining the repressed state of the K18 pro-
moter in NT cells. Altogether, our results strongly suggest
that the CtIP protein acts as an adapter molecule between
BRCA1 and CtBP1, allowing the recruitment of CtBP1 to
the preinitiation complex and the repression of the K18
promoter in NT cells.
Effect of internal deletion mutants of the E1A protein on the  activity of the K18 promoter Figure 5
Effect of internal deletion mutants of the E1A pro-
tein on the activity of the K18 promoter. (A) Sche-
matic representation of the structure of the mutants. 
Symbols are the same as in figure 3. (B) SW613-3 (T) and 
SW613-B3 (NT) cells were transfected with plasmid 
pK18(80)luc alone (none) or in the presence of the indicated 
E1A constructs. Results are presented as in figure 3. Error 
bars represent standard deviation of the mean of at least two 
experiments.BMC Molecular Biology 2005, 6:8 http://www.biomedcentral.com/1471-2199/6/8
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CtBP1 has a role in the stimulatory effect of E1A mutants on the K18 promoter Figure 6
CtBP1 has a role in the stimulatory effect of E1A mutants on the K18 promoter. (A) CtBP1 interacts with E1A-
N190 but not with the mutant E1A-N190-mut 281-282. GST pull-down assays were performed on extracts of SW613-3 (3) or 
SW613-B3 (B3) cells using GST alone (empty vector) or the fusion proteins GST-E1A-N190 or GST-E1A-N190-mut281-282. 
Bound proteins were analyzed by Western blotting with an anti-CtBP1 antibody. (B) Effect of the E1A-N190 or E1A-N190-
mut281-282 proteins on the activity of the K18 promoter. SW613-3 (T) or SW613-B3 (NT) cells were transfected with plas-
mid pK18(80)luc alone (none) or in the presence of plasmid pE1A-N190 or pE1A-N190-mut281-282 as indicated. Results are 
presented as in figure 3. Error bars represent standard deviation of the mean of duplicate experimental points. (C) Reversion 
of the stimulatory effect of E1A-N190 by CtBP1. SW613-3 (T) or SW613-B3 (NT) cells were transfected with plasmid 
pK18(80)luc alone (none) or in the presence of plasmid pE1A-N190 (2 µg) or pcDNA3-CtBP (24 µg) or with the three plas-
mids together, as indicated. Results are presented as in figure 3. Error bars represent standard deviation of the mean of tripli-
cate experimental points. (D) The CtBP1 protein has no direct effect on the activity of the K18 promoter. SW613-3 (T) or 
SW613-B3 (NT) cells were transfected with plasmid pK18(80)luc alone (none) or in the presence of various amounts of plas-
mid pcDNA3-CtBP, as indicated. Results are presented as in figure 3. Error bars represent standard deviation of the mean of 
triplicate experimental points.BMC Molecular Biology 2005, 6:8 http://www.biomedcentral.com/1471-2199/6/8
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Discussion
Differential activity of the K18 promoter and opposite 
effects of E1A mutants
We report here that the E1A protein isoforms (12S and
13S) and derivatives of E1A-13S that retain the N-terminal
first 29 aa inhibit the activity of the K18 promoter, specif-
ically in T-type cells of the SW613-S colon carcinoma cell
line. In contrast, derivatives of the viral protein which
have lost the inhibitory region but retain the C-terminal
region of E1A stimulate the activity of the K18 promoter,
specifically in NT cells. The two phenomena appear to be
exclusive: among more than 30 E1A mutants studied (this
work and unpublished results), none was found that
could both repress the activity of the promoter in T cells
and stimulate it in NT cells. This observation suggests that
the two phenomena are related and could result from
interference with the same and single mechanism. This is
further supported by the observation that the stimulatory
effect of mutant E1A-N25 is abolished in the presence of
the wild-type E1A protein (data not shown). We have
previously found that the differential activity of the K18
promoter between T and NT cells is a property of the
minimal promoter (K18(41)) [21]. The mechanism
responsible for this difference in activity does not involve
the binding of a factor to a specific sequence of the pro-
moter [22] but probably results from alterations of
protein-protein interactions within the preinitiation com-
plex. The same conclusion was reached here for the stim-
ulatory or inhibitory effects of the various E1A derivatives
on the activity of the K18 promoter. These effects were
observed with the minimal promoter and with all the
mutated versions of the K18 promoter tested. Altogether,
these results strongly suggest that both inhibitory and
stimulatory mutants of E1A exert their effect by interfering
with the very mechanism responsible for the differential
activity of the K18 promoter.
A functional domain of the E1A protein located in the 12–
25 region
We have found that a unique region of E1A, located
between aa 12 and 25, is involved in its inhibitory effect
on the activity of the K18 promoter. We previously
reported results which suggested that E1A is acting on the
p300 or CBP protein to inhibit the activity of the K18
promoter in T-type cells [23]. Two regions of the E1A pro-
tein, the N-terminal 1–28 region and the CR1 region, are
known to be involved in the interaction of the viral pro-
tein with p300/CBP [29]. Within the CR1 region, the
p300/CBP interacting domain is most probably located
between aa 66 and 72. In the N-terminal region, two
p300/CBP interacting domains have been identified. The
first one spans residues 2–10 of E1A and the second
domain is located between aa 19–28. It was shown
[30,31] that aa 11–22 are not essential for the binding of
E1A to p300/CBP. Thus, the 12–25 region involved in the
inhibition of the K18 promoter appears to be different
from the regions of interaction with the p300/CBP
proteins. Furthermore, we have found that mutants E1A-
ARG2 (R2G – data not shown), E1A-d2-11 and E1A-d61-
85 which can no longer bind to p300/CBP, still efficiently
inhibit the activity of the K18 promoter in T-type cells.
Altogether, our results lead us to conclude that, contrary
to what we suggested previously, inactivation of the p300/
CBP proteins is most probably not involved in this
Expression level of the E1A-N190 and CtBP1 constructs Figure 7
Expression level of the E1A-N190 and CtBP1 con-
structs. (A) SW613-B3 or SW613-3 cells were transfected 
with plasmid pE1A-N190 (wt) or pE1A-N190-mut281-282 
(mut). Cellular extracts were analyzed by Western blotting 
with an anti-E1A antibody. (B) SW613-3 (3) or SW613-B3 
(B3) cells were transfected with plasmid pcDNA3-CtBP or 
untransfected (mock). Cellular extracts were analyzed by 
Western blotting with an anti-CtBP1 antibody.BMC Molecular Biology 2005, 6:8 http://www.biomedcentral.com/1471-2199/6/8
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The BRCA1 protein has a role in the repression of the K18 promoter in NT cells Figure 8
The BRCA1 protein has a role in the repression of the K18 promoter in NT cells. (A) SW613-3 (T) or SW613-B3 
(NT) cells were transfected with plasmid pK18(80)luc alone (none) or in the presence of 24 µg of plasmids pCBRCA1C 
(BRCA1wt), pcDNA3-BRCA1(Y1853→STOP) or pcDNA3-BRCT, as indicated. Results are presented as in figure 3. Error bars 
represent standard deviation of the mean of three experiments. (B) and (C) Expression level of the BRCA1 constructs. 
SW613-3 (3) or SW613-B3 (B3) cells were untransfected (mock) or transfected with plasmid pCBRCA1C (wt), pcDNA3-
BRCA1(Y1853→STOP) (mut) or pcDNA3-BRCT, as indicated. Cellular extracts were analyzed by Western blotting with an 
anti-HA antibody.BMC Molecular Biology 2005, 6:8 http://www.biomedcentral.com/1471-2199/6/8
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inhibitory effect. It was reported that aa 1–21 and 55–60
of E1A are involved in its interaction with the PCAF factor
[32,33]. The 1–21 region has not been further investigated
so far to determine precisely the aa residues responsible
for binding to PCAF. However, since the E1A-d40-60
mutant retains an inhibitory potential on the activity of
the K18 promoter, this inhibition probably does not
involve the PCAF protein. Within the first N-terminal 80
aa of E1A, the 12–26 region has the highest score for the
probability of forming an α-helix and this property is con-
served through five adenovirus serotypes [34]. The RAP30
subunit of TFIIF and the TATA-box binding protein (TBP)
were shown to interact in vitro with aa 1–29 of E1A [35].
Severino et al [36] reported that aa 1–36 of E1A are
responsible for the interaction with the RACK1 protein.
We have screened a cDNA library by the yeast two-hybrid
system using aa 12–29 of E1A as a bait. Clones
corresponding to the glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH), the UREB1 and the MYCBP proteins
have been isolated (OB, ML, unpublished results). Exper-
iments are in progress to determine if one of these factors
is involved in the regulation of the K18 promoter in
SW613-S cells.
A role for CtBP1 and BRCA1 in the regulation of the K18 
promoter
E1A mutants that have lost the 12–25 inhibitory region,
acquired a stimulatory potential on the activity of the K18
promoter, specifically in NT cells, provided that they
retain the C-terminal region of the viral protein. Within
this region, aa 281–282, which are part of the CtBP1 bind-
ing site, are essential to the stimulatory effect and an
excess of CtBP1 protein abolishes this effect. The CtBP1
protein is a corepressor, which represses promoters by
HDAC-dependent or HDAC-independent mechanisms.
We have previously shown [23] that the activity of the K18
promoter is stimulated by HDAC inhibitors (sodium
butyrate or trichostatin), specifically in NT cells. We also
made the observation that the K18 promoter could be
stimulated in NT cells by forced recruitment to the pro-
moter of a GAL4 fusion protein containing the histone
acetyl-transferase (HAT) domain of CBP or of an acidic
activator (GAL4-VP16) known to interact with HAT com-
plexes. Mutations of aa residues involved in the HAT activ-
ity of CBP or in the interaction of VP16 with HAT
complexes strongly reduced the stimulation. We conclude
that the activity of the K18 promoter is repressed in NT
cells by a mechanism involving the CtBP1 and HDAC
proteins. CtBP1 is most probably acting through an
HDAC-dependent mechanism because (i) we have
reported [23] that the stimulatory effects by sodium
butyrate and by the E1A-∆CR1 mutant are not additive;
(ii) forced recruitment of a GAL4-CtBP1 fusion protein on
a K18 promoter engineered with GAL4 binding sites
strongly inhibits the activity in both T and NT cells and
this inhibition cannot be reversed by sodium butyrate
(CD, unpublished results). These last results indicate that
CtBP1 can inhibit the K18 promoter by an HDAC-inde-
pendent mechanism but in this case, inhibition is not cell
type specific. Stimulation of the activity of the K18 pro-
moter by some E1A mutants in NT cells is most likely due
to a relief of the repressive mechanism operating in these
cells. The fact that these mutants have no stimulatory
effect in T-type cells suggests that the high activity of the
promoter reflects a reversal of the same repression mech-
anism, possibly through the expression of some constitu-
tively high histone/factor acetyl-transferase (HAT/FAT)
activity in these cells (see below). Our results are in agree-
ment with those obtained by others. Grooteclaes et al.
[37] reported that the K18 gene is derepressed in embryo
fibroblasts from mice with homozygous compound
knockout of the CtBP1 and CtBP2 genes. In addition, the
K18 gene is repressed in knockout cells infected with a
CtBP1 retroviral vector. Schuierer et al. [38] found that the
E1A protein activates the expression of the AP2α gene by
interfering with CtBP1. Sundqvist et al. [39] have reported
that the CtBP1 interacting region of E1A relieves the
HDAC-dependent repression of transcription by CtBP1.
We propose that CtBP1 and associated HDAC could be
recruited to the preinitiation complex by a BRCA1/CtIP
complex. Such a role for BRCA1 was not reported previ-
ously although it is known that BRCA1 is associated with
the RNA polymerase II holoenzyme. Some examples of
transcriptional repression by BRCA1 were reported. It
represses c-MYC-mediated stimulation of the human tel-
omerase reverse transcriptase promoter [40]. BRCA1 func-
tions as a corepressor for the transcriptional repressor
ZBRK1 [41]. Experiments using DNA microarrays have
indicated that the BRCA1, CtBP1, CtBP2 and CtIP genes
are expressed at comparable levels in T and NT cells of the
SW613-S cell line (C. Lavialle, personal communication).
This was also the case for genes coding for HDAC-1 to -4
and HDAC-6 to -10. The HDAC-5 gene was found to be
overexpressed 3.4 fold in NT cells, as compared to T cells,
and this was confirmed by Western blot analysis. How-
ever, in transient expression assays, the activity of the K18
promoter was unaffected by overproducing the HDAC-5
protein, both in T and NT cells (CD, unpublished results),
indicating that the low level of accumulation of HDAC-5
in T-type cells is not responsible for the high activity of the
promoter in these cells. It could be argue that a gene cod-
ing for one of these factors is specifically mutated in T
cells. This seems highly unlikely since the K18 promoter is
also deregulated in stable transfectants obtained from NT
cells using a c-MYC expression vector and which acquired
all the phenotypic properties of T-type cells (PP, unpub-
lished results).BMC Molecular Biology 2005, 6:8 http://www.biomedcentral.com/1471-2199/6/8
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A model for the differential activity of the K18 promoter
To summarize the observations we made on the differen-
tial regulation of the K18 promoter between T and NT
cells of the SW613-S cell line, we propose the model pre-
sented in figure 9. Several aspects are still speculative but
it is compatible with all the results we have obtained so
far. The expression level of the K18 gene in NT cells is
comparable to that observed in normal epithelial cells of
human colon [42]. Our results indicate that, in NT cells,
the K18 promoter is in fact subjected to a repression
mechanism involving the CtBP1 protein and HDACs,
probably in order to keep in check the expression level of
the K18 gene. The data presented suggest that CtBP1 and
associated HDACs could be recruited to the preinitiation
complex by a BRCA1/CtIP complex (Fig. 9A). In our
model, the target of HDACs is a factor (S), whose acetyla-
tion level is controlled by a balance between HDAC and
HAT/FAT activities. The activity of the K18 promoter
would be dependent on the acetylation level of S. We have
reported previously that the acetylation state of histones
H3 and H4, as well as the structure of the chromatin, are
the same in T and NT cells in the region of the K18 pro-
moter [23]. In addition, the mechanism responsible for
the differential activity is acting on the minimal promoter
and no specific sequence is required. Therefore, we pro-
pose that S is a non-histone protein which is a component
of the preinitiation complex and is acetylated by a FAT
activity.
In T-type cells, the FAT activity recruited to the preinitia-
tion complex would be higher, because the enzyme is
overproduced or more active in these cells. The high FAT
activity would shift the balance toward an hyperacetylated
state of S. We propose that this protein with FAT activity
(F) is the target of the 12–25 domain of E1A (Fig. 9B). The
viral protein, or its mutant forms retaining a functional
12–25 domain, would inhibit the FAT activity. This would
result in the inhibition of the promoter. It is very likely
that the factor with FAT activity is not the p300/CBP or
PCAF proteins because we identified E1A mutants
disabled in their capacity to bind to these factors but that
are still able to efficiently inhibit the activity of the pro-
moter in T-type cells. In the context of our model and as a
novel candidate FAT activities, it is interesting to note
recent reports describing the autoacetylation of the
general transcription factor TFIIB [43] and of the RAP30
subunit of TFIIF [44].
E1A mutants with no functional 12–25 domain but
retaining the C-terminal PLDLS motif would prevent by
competition the recruitment of CtBP1 and HDACs to the
preinitiation complex (Fig. 9C). In NT cells, this would
shift the balance towards hyperacetylation of S despite the
low FAT activity of the F protein, resulting in a stimulation
of the promoter. Such mutants are not expected to have an
effect in T-type cells since the high FAT activity in these
cells already supersede that of HDACs. Finally, the pro-
posed model offers an explanation to the observation that
inhibition of the promoter in T cells and stimulation in
NT cells are apparently exclusive phenomena. Indeed,
according to the model, no E1A mutant is expected to
have both capabilities.
Conclusion
The promoter of the keratin 18 gene is deregulated in cells
of the human colon carcinoma cell line SW613-S by an
unusual mechanism that is acting on the minimal pro-
moter and involves alteration of an acetylation
mechanism acting on a non-histone substrate. We report
here that the adenoviral E1A protein and some of its
mutants specifically interfere with this mechanism
through two regions of the protein: the C-terminal CtBP1
binding domain and a domain spanning aa 12–25. Our
results lead us to conclude that, in colon epithelial cells,
the expression level of the K18 gene is kept in check by a
repression mechanism involving the CtBP1, HDAC and
BRCA1 proteins. This mechanism is altered in SW613-S
colon carcinoma cells that overexpress the K18 gene. Since
it is acting at the level of the preinitiation complex, its
alteration most probably participates in the deregulated
expression of many genes in these tumor cells.
Methods
Cell lines, transfection and luciferase assays
The origin of the SW613-S cell line and cell culture condi-
tions have been described previously [10,16]. Clones
SW613-3 (T-type cells) and SW613-B3 (NT-type cells)
were used in this study. Transfection and luciferase assays
were performed in triplicate for each construct in each
experiment, as described previously [21,22] and six
micrograms of each plasmid were used, unless otherwise
stated. In cotransfection experiments where the reporter
plasmid was co-introduced with expression vectors cod-
ing for various polypeptides, the reference assay com-
prised cells transfected with the reporter plasmid and with
an amount of empty vector corresponding to the molar
equivalent of the expression vector used. In each experi-
ment, the two cell types were also transfected in parallel
with the pSVluc construct and the activity of every pro-
moter construct was expressed relative to that of the SV40
early promoter. We have shown previously that this viral
promoter is equally active in both cell types [21]. This is
also the case for the human cytomegalovirus IE1 gene pro-
moter which drives the expression of the various polypep-
tides encoded by the vectors used in co-transfection
experiments (CD, unpublished observations).
Plasmids constructions
Construction of plasmids pK18(41)luc, pK18(80)luc and
pSVluc has already been reported [22]. Plasmids pE1A-BMC Molecular Biology 2005, 6:8 http://www.biomedcentral.com/1471-2199/6/8
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A model for the putative mechanism responsible for the differential activity of the K18 promoter and for the effect of the dif- ferent E1A mutants Figure 9
A model for the putative mechanism responsible for the differential activity of the K18 promoter and for the 
effect of the different E1A mutants. The E1A full-length protein is represented at the top with emphasis on the two 
domains of interest: aa 12 to 25 and the PLDLS motif. The horizontal line represents the DNA and the initiation site is symbol-
ized by an arrow, whose thickness is an indication of the activity of the promoter. (A) Functioning of the K18 promoter in T 
and NT cells. The F factor is an as yet unidentified protein which has a HAT/FAT activity and is supposedly more abundant or 
more active in T cells (bold) than in NT cells. F acetylates (Ac) the substrate protein S, a non-histone protein whose acetylation 
level controls the activity of the K18 promoter. The acetylation level of S is also under the control of HDAC proteins. The 
CtBP1 protein interacts with the PLDLS motif of the CtIP protein. CtBP1 associates with some HDAC proteins by a domain 
that is different from the one recognizing the PLDLS motif [4, 48]. The recruited HDAC proteins deacetylate the S substrate in 
NT cells where the acetylase activity is already weak and this down-regulates the promoter. CtIP is an interaction partner of 
BRCA1 which is represented here as part of the preinitiation complex (PIC). (B) Effects of C-terminal deletion mutants of E1A 
on the activity of the K18 promoter in T and NT cells. The binding of these mutants to the F factor through the 12–25 domain 
results in a low HAT/FAT activity, deacetylation of S and inhibition of the promoter in T cells. These mutants are expected to 
have little effect in NT cells since the level of acetylation of S is already low in these cells. (C) Effects of N-terminal deletion 
mutants of E1A on the activity of the K18 promoter. The C-terminal part of E1A contains the PLDLS motif which permits its 
interaction with CtBP1. The displacement of CtBP1 from CtIP prevents the recruitment of HDAC proteins to the preinitiation 
complex. This is of no consequence in T cells where the S protein is maintained in an hyperacetylated state by the high HAT/
FAT activity. In contrast, in NT cells removal of HDAC proteins allows the weak HAT/FAT activity to acetylate S to a high 
level which results in a stimulation of the promoter.BMC Molecular Biology 2005, 6:8 http://www.biomedcentral.com/1471-2199/6/8
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13S, pE1A-C249, -C192, -C139, -C109, -C79, -N25, -N76,
-N120, -N132 [33] were given to us by Dr R.M. Evans
(Salk Institute for Biological sciences, La Jolla, USA). Plas-
mids pE1A-d2-11 and pE1A-d26-35 [45] were gifts of Dr.
M. Fuchs (Dana-Farber Cancer Institute, Boston, USA).
Plasmids pcDNA3-CtBP and pGEX-CtBP [6,39] coding for
the human CtBP1 protein were given to us by Dr. C. Sven-
sson (Uppsala University, Sweden). Plasmids pCBRCA1C
(coding for wild type BRCA1) and pcDNA3-
BRCA1(Y1853→STOP) were provided by Dr J. Feunteun
(Institute Gustave Roussy, Villejuif, France). A fragment
coding aa 1640 to 1864 of BRCA1 was amplified by the
polymerase chain reaction (PCR) from plasmid
pGEX4T1-BRCT [46], a gift from Dr N. Dalla Venezia
(Université Médicale Rockefeller, Lyon, France), and
inserted into the vector pcDNA3. A DNA fragment coding
for 3 tag HA motifs was then inserted upstream of the
BRCT coding region to yield plasmid pcDNA3-BRCT.
Plasmid pE1A-d30-76 was obtained by inserting into plas-
mid pE1A-N76 a fragment amplified by PCR from plas-
mid pE1A-13S and coding for aa 1 to 29 of E1A. For all
E1A constructs, aa numbering refers to the E1A-13S
isoform. Plasmids pE1Ad30-45, pE1A-d40-60, pE1A-d61-
85 were constructed by inserting into the pCMX-PL1 vec-
tor two fragments coding respectively for aa 1–29 and 46–
289, 1–39 and 61–289 or 1–60 and 86–289 of E1A-13S.
Plasmid pE1A-d12-25 was obtained by inserting into
plasmid pE1A-N25 a double-stranded synthetic oligonu-
cleotide coding for aa 1 to 11. Plasmid pE1A-C29 was
derived from plasmid pE1A-d30-76 by deleting the
sequence corresponding to aa 77 to 289. Plasmids pE1A-
N190 and pE1A-N190-mut281-282 were constructed by
inserting into the pCMX-PL1 vector a fragment amplified
by PCR coding respectively for the wild type sequence of
aa 190 to 289 or a sequence with two mis-sense mutations
on aa 281 (D→A) and 282 (L→S). The same PCR frag-
ments were also inserted into plasmid pGEX-1LambdaT
coding the glutathion-S-transferase (GST) protein to
obtain plasmids pGEX-E1A-N190 and pGEX-E1A-N190-
mut281-282. All constructs coding for E1A proteins were
checked by sequencing.
GST-pull down assays
A 40 ml overnight culture of bacteria transformed with the
appropriate plasmid was diluted 10-fold with culture
medium and incubated for one hour at 37°C with shak-
ing. Induction was for 3 hours in the presence of isopro-
pylthiogalactoside (1 mM). The bacteria were pelleted by
centrifugation (10 min, 4000 rpm), resuspended in 20 ml
of phosphate-buffered saline (PBS) containing Complete
Inhibitor EDTA free (Roche) and 1 mM phenyl-methyl-
sulfonyl fluoride (PMSF) (Sigma) and disrupted by soni-
cation (twice 15 s, 50% of full power). The suspension
was adjusted to 1% of Triton X-100 and incubated for 30
min at 4°C. After centrifugation (30 min, 13 000 rpm,
4°C), the supernatant was collected and stored at -80°C
as one ml aliquots. The concentration of the GST-fusion
protein was determined by purifying it from a one ml aliq-
uot using glutathione beads. Quantification was carried
out by migration on a polyacrylamide gel, using a range of
known quantities of bovine serum albumin as a standard.
For the pull-down assays, 10 µg of GST fusion proteins
and 50 µl of a 50% slurry of glutathione Sepharose 4B
beads (Pharmacia Biotech) were mixed and diluted to 1
ml with PBS. Incubation was for 2 hours at 4°C with gen-
tle shaking. Beads were washed twice with PBS and once
with the protein extraction buffer (50 mM Tris-HCl pH
7.5, 150 mM NaCl, 1% NP40 and 1 mM EDTA). The
beads were incubated with cellular protein extracts for 2
hours at 4°C, washed with protein extraction buffer and
boiled in loading buffer.
Western blotting
Samples of cellular extracts (300 µg of proteins) or from
the pull-down assays were analyzed by migration on 15%
SDS-polyacrylamide gels (6% for the BRCA1 and
BRCA1(Y1853→STOP) proteins). Western blotting onto
nitrocellulose membranes was performed using a semi-
dry transfer procedure [47] or a liquid transfer method
(400 mA overnight in a Tris-base 25 mM, glycin 200 mM
solution) in the case of BRCA1. Blocking of the mem-
brane and incubation with the antibody were performed
in a solution containing 10 mM Tris-HCl pH 8.0, 150 mM
NaCl, 0.05% Tween 20 and 5% dry low-fat milk. The
mouse monoclonal anti-HA antibody was a gift from Dr.
S. Leibovitch (Institute Gustave Roussy, Villejuif, France).
Anti-E1A (SC430) and anti-CtBP1 (SC11390) rabbit pol-
yclonal antibodies were obtained from Santa-Cruz Bio-
technology, Inc.
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